Butyrate supplementation in CKD models has been found to alleviate kidney fibrosis and reduce inflammation by modulating pathways such as NLRP3-mediated pyroptosis and the STING/NF-κB/p65 pathway [81]. The gene discussed is NFKB1; the disease is chronic kidney disease.